Evidence for a causal role of the renin-angiotensin system in nitrate tolerance

Circulation. 1999 Jun 22;99(24):3181-7. doi: 10.1161/01.cir.99.24.3181.

Abstract

Background: We have previously shown that nitroglycerin (NTG) therapy increases vascular expression of endothelin 1 (ET-1) and stimulates vascular superoxide (O2.-) production via activation of NADH/NADPH oxidases. Both phenomena are stimulated by angiotensin II in vitro, and the renin-angiotensin system is activated during early nitrate therapy. We hypothesized that either angiotensin II or ET-1 may increase vascular O2.- production during nitrate therapy.

Methods and results: In New Zealand White rabbits, 3 days of treatment with NTG patches increased plasma renin activity for the entire treatment period. After 24 hours of NTG treatment, angiotensin II type 1 (AT1) receptor expression and vascular ACE activity were significantly decreased. At this time, constrictions to angiotensin I and II were depressed, but there was no loss of NTG vasodilator potency. Within 3 days of continuous NTG treatment, relaxations to NTG were markedly blunted. This was associated with an increase in AT1 receptor mRNA expression, a return of ACE activity back to baseline, and a marked increase in constrictions to angiotensin I and II despite continuously increased plasma renin activity. Tolerance was associated with a 2-fold increase in vascular O2.-, as estimated by lucigenin-enhanced chemiluminescence. Concomitant treatment with the AT1 receptor antagonist losartan (5 to 25 mg. kg-1. d-1) dose-dependently normalized vascular O2.- and prevented tolerance to NTG and cross-tolerance to endogenous nitric oxide released by acetylcholine. The nonselective ET-1 receptor blocker bosentan (100 mg. kg-1. d-1) had similar but less pronounced effects.

Conclusions: The positive effects of AT1 and ET-1 receptor blockade on tolerance and O2.- production imply a pathophysiological role for angiotensin II and to some extent for ET-1 in the development of nitrate tolerance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Angiotensin I / pharmacology
  • Angiotensin II / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology
  • Bosentan
  • Dose-Response Relationship, Drug
  • Drug Tolerance
  • Endothelium, Vascular / chemistry
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / enzymology
  • Female
  • Gene Expression / drug effects
  • Losartan / pharmacology
  • Luminescent Measurements
  • Male
  • Multienzyme Complexes / metabolism
  • NADH, NADPH Oxidoreductases / metabolism
  • NADPH Oxidases / metabolism
  • Nitrates / metabolism*
  • Nitric Oxide / metabolism
  • Nitroglycerin / pharmacology*
  • Peptidyl-Dipeptidase A / metabolism
  • RNA, Messenger / analysis
  • Rabbits
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Receptors, Angiotensin / genetics
  • Renin / blood
  • Renin-Angiotensin System / drug effects*
  • Renin-Angiotensin System / physiology*
  • Sulfonamides / pharmacology
  • Superoxides / metabolism
  • Vasoconstriction / drug effects
  • Vasoconstriction / physiology
  • Vasodilation / drug effects
  • Vasodilation / physiology
  • Vasodilator Agents / pharmacology*

Substances

  • Antihypertensive Agents
  • Multienzyme Complexes
  • Nitrates
  • RNA, Messenger
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Receptors, Angiotensin
  • Sulfonamides
  • Vasodilator Agents
  • Superoxides
  • Angiotensin II
  • Nitric Oxide
  • Angiotensin I
  • NADH oxidase
  • NADH, NADPH Oxidoreductases
  • NADPH Oxidases
  • Peptidyl-Dipeptidase A
  • Renin
  • Nitroglycerin
  • Losartan
  • Bosentan